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Abstract: Microalbuminuria is associated with hypertension and is a strong risk factor for subsequent chronic disease, both 
renal and coronary heart disease (CHD), Presently there are several methods available for measurement of microalbuminuria.
The aim of this study was to evaluate if the three different methods gave similar information or if one of the assays were 
superior to the others. Blood pressure, inﬂ  ammatory markers and cardiovascular mortality and morbidity were correlated 
with urine albumin analysed with a point-of-care testing (POCT) instrument, nephelometric determination of albumin and 
albumin/creatinine ratio in elderly males. The study population consisted of 103 diabetic and 603 nondiabetic males (age 
77 years) in a cross-sectional study. We analyzed urine albumin with a HemoCue
® Urine Albumin POCT instrument and a 
ProSpec
® nephelometer and albumin/creatinine ratio. There were strong correlations between both systolic and diastolic 
blood pressure and all three urine albumin methods (p < 0.0001). There were also signiﬁ  cant correlations between the dif-
ferent urine albumin measurements and serum amyloid A component, high-sensitivity C-reactive protein and interleukin-6. 
The three different urine albumin methods studied provided similar information in relation to cardiovascular disease. There 
was a strong correlation between systolic and diastolic blood pressure and microalbuminuria in both the whole study 
population and in nondiabetic males emphasizing the role of hypertension in glomerular damage. The good correlation 
between the studied urine albumin measurements show that all three methods can be used for monitoring urine albumin 
excretion.
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Introduction
Hypertension is a highly prevalent disorder that affects the majority of adults (Wang et al. 2005). It is 
also an important risk factor for myocardial infarction and stroke and it constitutes a major source of 
cardiovascular morbidity and mortality (Stamler et al. 1993) Experimental and physiological studies 
support an important role for the kidneys in the pathogenesis of essential hypertension (Cowley and 
Roman, 1996). In animal hypertension models, one of the earliest ﬁ  ndings is a defect in renal sodium 
excretion resulting in elevated glomerular pressures that leads to endothelial dysfunction and hyperﬁ  l-
tration (Kurokawa, 1995). Previous studies have indicated that microalbuminuria may be a feature of 
hypertension and a marker of kidney damage in patients with hypertension (Winocour et al. 1992; 
Horner et al. 1996; Cirillo et al. 1998). 
Prevention of nephropathy is one of the most important challenges for modern health care. Moderate 
chronic renal insufﬁ  ciency is a disorder with increasing prevalence, particularly in the elderly. In the 
United States, there are approximately 12.5 million individuals with creatinine clearance less than
50 mL/min/1.73m
2 (Hsu et al. 2000).
 Mild to moderate chronic renal insufﬁ  ciency is a risk factor for 
acute kidney failure and end-stage renal disease. It is thus important to treat these patients early to 
prevent them from developing severe kidney damage.
There is an increasing demand for urine albumin tests suitable for point-of-care testing (POCT). 
POCT offers rapid test results, which facilitates the use of the results to motivate the patient to lifestyle 
changes and increased compliance (Lehman, 2002; Price, 2000; St-Louis, 2001). To achieve good 
compliance it is essential that the patient and physician work together and that the patient get regular 
feedback on the treatment results. The feedback is considered to be more effective if the test results are 
available during the consultation. This requires that the patient either provides blood samples prior to 
the consultation or that the care unit has a capability to perform rapid testing of relevant markers. This Analytical Chemistry Insights 2008:3 70
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has led to the development of POCT instruments 
for urine albumin excretion.
The aim of the present study was to correlate 
hypertension with different markers for microal-
buminuria in a group of elderly males. The methods 
used in the study were HemoCue
® urine albumin 
(POCT instrument), a central laboratory instrument 
(ProSpec
®) and albumin/creatinine ratio (ACR).
Methods
Study population
This study is a cross-sectional investigation of 
Swedish men, 77 years of age, which were partic-
ipants in Uppsala Longitudinal Study of Adult Men 
(ULSAM) (Helmersson et al. 2004). This health 
survey to identify risk factors for cardiovascular 
disease (CVD) started in 1970; when all men born 
between 1920–1924, and living in Uppsala, were 
originally invited to participate (aged 50). These 
men were reinvestigated at age 77. The study was 
approved by the Ethics Committee at Uppsala 
University and all participants gave their informed 
consent prior to blood sampling. All clinical 
experimentation described in the manuscript was 
conducted in accordance with the guidelines 
proposed in the Declaration of Helsinki.
Sample collection 
Twenty-four hour urine was collected without 
additives. Blood samples were drawn from an 
antecubital vein in the morning after a 12-hour 
(overnight) fast. The samples were immediately 
frozen at –70°C until analysis. The same urine 
samples were used for all three assays.
Medical history, medication and 
diabetes-deﬁ  nition
Medical history and information on medication 
were obtained by a self-administered question-
naire. A total of 706 urine samples were analysed. 
The patients completed a questionnaire and had a 
fasting plasma glucose value. Type 2 diabetes was 
diagnosed according to the WHO definition: 
fasting plasma glucose ≥7.0 mmol/L, or intake of 
oral anti-diabetic drugs alone, or in combination 
with insulin treatment (n = 103). Control men had 
plasma glucose <7.0 mmol/L and no anti-diabetic 
drug (n = 603). Information of a history of CVD 
(myocardial infarction, ischemic stroke or angina 
pectoris) was obtained from the Swedish Hospital 
Discharge Registry. In the study population, 44.3% 
of the participants had hypertension, 24% had 
ischemic heart disease (including myocardial 
infarction), 16% had a history of myocardial infarc-
tion, 18% had cerebrovascular diseases (including 
stroke) and 16% had a history of stroke.
Urine albumin
Urine albumin was analyzed with HemoCue
® urine 
albumin (HemoCue
®, Ängelholm, Sweden). CV 
calculated on duplicate samples was 3.9%. Urine 
albumin was also measured by nephelometry 
(Urine albumin, Dade Behring, Deerfield, IL, 
U.S.A.) using a Behring BN ProSpec
® analyzer 
(Dade Behring). The total analytical imprecision 
of the method was 3.7% at 9.5 mg/L and 5.0% at 
85 mg/L. Urine creatinine were analyzed with a 
modiﬁ  ed kinetic Jaffe reaction on an Architect 
Ci8200
® analyzer (Abbott, Abbot Park, IL, U.S.A.) 
and reported as S.I. units (µmol/L) and creatinine 
related urine albumin was calculated from the 
Prospec
® results. The total analytical imprecision 
of the creatinine method was 4.8% at both 94 and 
337 µmol/L. All assays were performed indepen-
dently without prior knowledge of other patient 
data.
Assays of interleukin (IL)-6 and
high-sensitivity C-reactive protein 
(hsCRP) and serum amyloid
A component (SAA)
High sensitivity IL-6 was analyzed by an ELISA 
kit (IL-6 HS, R&D Systems, Minneapolis, MN, 
U.S.A.). The total CV of the method was 7% and 
interassay coefﬁ  cient of variation (CV) was 5%. 
High sensitivity CRP and SAA measurements were 
performed by latex enhanced reagent (Dade 
Behring, Deerﬁ  eld, IL, U.S.A.) using a Behring 
BN ProSpec analyzer (Dade Behring). The 
intraassay CV of the CRP method was 1.4% at both 
1.23 mg/L and 5.49 mg/L and the intraassay CV 
of the SAA method was 5.9% at 12.8 mg/L and 
3.2% at 81.7 mg/L.
Statistical calculations
All urine albumin values below the detection 
limits (10 mg/L for HemoCue
® and 3 mg/L for 
ProSpec
®) was assigned the value of the respective 
detection limit in the statistical analysis. When the Analytical Chemistry Insights 2008:3 71
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ProSpec
® urine albumin values were below 3 
mg/L, ACR could not be calculated by the labora-
tory information system. In the statistical analysis 
these cases was assigned an ACR of 0.3 g/mol 
creatinine.
All calculations were performed with the statis-
tical software package Stata 6.0 (Stata Corporation, 
College Station, Texas, U.S.A.). Differences 
between diabetic patients and controls were tested 
with Mann-Whitney test, Kruskal Wallis test or 
partial correlation in multivariate analyses. Asso-
ciations between continuous variables were tested 
with Spearman’s rank correlation analysis. P-values 
<0.05 were regarded as statistically signiﬁ  cant 
throughout the study.
Results
Correlation between urine albumin 
measured with HemoCue
® and 
ProSpec
® and ACR
There was a strong correlation between duplicate 
analysis of 100 samples on Hemocue
® (R
2 = 0.999). 
There were also good agreements between the two 
urine albumin methods (R
2 = 0.956) (Figure 1) and 
between ProSpec
® and ACR (R
2 = 0.937) (results 
not shown). The Hemocue
® method gave slightly 
lower values than ProSpec
®.
Prevalence of microalbuminuria 
in nondiabetic males
114 (18.9%) of the nondiabetic males had urine 
albumin >20 mg/L and 101 (16.7%) individuals 
had urine albumin >25 mg/L with the HemoCue
® 
instrument. The corresponding ﬁ  gures for ProSpec
® 
were 124 (20.6%) and 106 (17.6%), respectively. 
111 (18.5%) of the nondiabetic males had creati-
nine related urine albumin >2.5 g/mol creatinine 
and 102 (17%) individuals had values >3 g/mol 
creatinine.
Urine albumin and laboratory markers
No signiﬁ  cant correlations were found between 
any of the microalbuminuria measurements and 
total cholesterol, HDL-cholesterol or LDL-choles-
terol in either the whole study group or the nondi-
abetic group. In contrast, most of the correlations 
were signiﬁ  cant with triglycerides and the inﬂ  am-
matory markers hsCRP, IL-6 and SAA. The most 
pronounced correlations were found with SAA. 
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Figure 1. Comparison between urine albumin analyzed with HemoCue® and Prospec® in the range 10-150 mg/L in non-diabetic males. 
Bland-Altman plot presenting mean of the two measurements (x-axis) versus the difference (HemoCue® - Prospec®) between the two 
measurements (y-axis). Analytical Chemistry Insights 2008:3 72
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Signiﬁ  cant correlations are presented as Spearman 
rank correlations in Table 1.
Urine albumin, cardiovascular disease 
and pharmaceutical treatment
There were signiﬁ  cant correlations between urine 
albumin values and cardiovascular disease and 
angina but not with ischemic stroke, myocardial 
infarction and cardiac failure (Table 1). The only 
signiﬁ  cant correlation between urine albumin and 
pharmaceutical treatment was noted for treatment 
with calcium antagonists.
Discussion 
The traditional reagent strips for measuring protein-
uria are not sensitive enough for monitoring urine 
albumin concentrations below 100–300 mg/L, 
thence they do not have sufﬁ  cient sensitivity to 
measure microalbuminuria. Microalbuminuria is 
currently measured by high pressure liquid chroma-
tography (HPLC) and a variety of immunochemical 
methods, such as radioimmunoassays, enzyme-
linked immunoassays, nephelometric and turbidi-
metric assays (Newman et al. 2005). The instrumen-
tation employed for these assays often limits the use 
to central laboratories. A few immunoassay-based 
Table 1. Spearman Rank correlations between urine albumin values and blood pressure, laboratory markers, 
medication and cardiovascular disease. Only correlations with a p value <0.05 for the whole population is 
presented.
  All males  Nondiabetic males
 r  r
Systolic blood pressure
U-albumin, HemoCue
® 0.237  0.234
U-albumin, ProSpec
® 0.269  0.272
ACR 0.267  0.272
Diastolic blood pressure
U-albumin, HemoCue
® 0.187  0.176
U-albumin, ProSpec
® 0.211  0.210
ACR 0.213  0.207
Triglycerides
U-albumin, HemoCue
® 0.106  NS
U-albumin, ProSpec
® 0.140  0.129
ACR 0.131  0.108
HsCRP
U-albumin, HemoCue
® 0.119  0.128
U-albumin, ProSpec
® 0.119  0.105
ACR 0.101  NS
SAA
U-albumin, HemoCue
® 0.163  0.165
U-albumin, ProSpec
® 0.170  0.144
ACR 0.183  0.152
IL-6
U-albumin, HemoCue
® 0.150  0.125
U-albumin, ProSpec
® 0.118  0.085
ACR 0.112  NS
Angina
U-albumin, HemoCue
® 0.112  0.120
U-albumin, ProSpec
® 0.120  0.133
ACR 0.137  0.138
Cardiovascular disease
U-albumin, HemoCue
® 0.123  0.101
U-albumin, ProSpec
® 0.093  NS
ACR 0.113  0.084
Calcium antagonists
U-albumin, HemoCue
® 0.144  0.143
U-albumin, ProSpec
® 0.134  0.141
ACR 0.147  0.151Analytical Chemistry Insights 2008:3 73
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microalbuminuria tests for point-of-care use have 
been introduced, such as the Bayer Clinitek 50
®, 
DCA 2000
® and HemoCue
® (Parson et al. 1999a; 
Parsons et al. 1999b; von Schenck, 2003).
Screening for microalbuminuria are usually 
performed by one of these methods: measurement 
of total urine albumin in 12 or 24 h collection, 
measurement of the albumin-to-creatinine ratio in 
morning urine or random sample or measurement 
of urine albumin in morning urine (American 
Diabetes association 2005). The 24 h collection is 
time consuming and thus expensive and requires 
highly motivated patients and careful information 
and it is often difﬁ  cult to perform in routine praxis. 
Urine albumin concentrations are standardised for 
concurrent creatinine excretion thus obtaining 
ACR. This procedure is based on the concept that 
creatinine excretion is stable and corrects for 
unknown urine volumes. Repeated measurements 
has shown that albuminuria is twice as variable as 
creatininuria (Pedrinelli et al. 2001). However, ACR 
often do not take into account male/female differ-
ences and the effect of reduced muscle mass, espe-
cially in elderly patients, is usually not adjusted for. 
Plasma creatinine is also known to be inﬂ  uenced 
by the diet and the plasma creatinine will inﬂ  uence 
the urine creatinine. The analytical quality of the 
creatinine method will inﬂ  uence ACR and there is 
also an economical aspect of the question, as ACR 
requires an additional urine creatinine analysis. All 
these factors should be considered when deciding 
on which screening method to use.
The lower cut-off values for microalbuminuria 
varies between studies, but it is often in the range 
of 15–25 mg/L for albuminuria and 1.8–3 g 
albumin/mol creatinine for ACR (Bakker, 1999; 
De Cosmo et al. 2005). The European urinanalysis 
guideline for ACR is 3.0 g/mol (European confed-
eration of laboratory medicine, 2000), which also 
is the Swedish laboratory recommendation. The 
detection limits for both HemoCue
® and ProSpec
® 
are sufﬁ  cient to detect even low levels of micro-
albuminuria.
ProSpec
® gave slightly higher values than 
HemoCue
® (Fig. 1) which also was reﬂ  ected in a 
higher number of patients with microalbuminuria 
when analyzed with ProSpec
®. However, there was 
a good agreement between the HemoCue
® and 
ProSpec
® quantiﬁ  cation of urine albumin especially 
considering that presently there is an international 
calibrator for serum but not for urine albumin 
(Whicher, 1998). Presently, the International 
Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) is planning a work group for 
preparation of an international calibrator for urine 
albumin. Such a calibrator is highly needed, as the 
treatment recommendations for microalbuminuria 
are international and should not be dependent on 
the method used. There should also be an interna-
tional calibrator for urine creatinine for ACR. 
We found strong correlations between albumin-
uria and blood pressure, triglycerides, hsCRP and 
SAA. There were also signiﬁ  cant correlations 
between urine albumin and cardiovascular disease 
and angina but not with death due to myocardial 
infarction, heart failure or stroke. This may be due 
to the difference in events. There were considerable 
more patients suffering from cardiovascular disease 
than the number of patients that died due to 
myocardial infarction. A longer follow up period 
may have resulted in more signiﬁ  cant correlations 
with the mortality and morbidity markers. There 
was a positive correlation between urine albumine 
excretion and use of calcium antagonists but not 
with the other antihypertensive drugs. The positive 
correlation is a bit unexpected, as one of the aims 
of the antihypertensive treatment is to reduce albu-
minuria. However, this may be due to a treatment 
bias as the choice of drugs may be inﬂ  uenced by 
the albuminuria. 
In conclusion, this study shows a good correla-
tion between urine albumin analysed with 
HemoCue
® POCT instrument, a central laboratory 
instrument (ProSpec
®) and ACR in a group of 
elderly males showing that all three methods can 
be used for monitoring urine albumin excretion. 
Age, sex and ethnicity composition were homog-
enous in this study, but the results may therefore 
have limited generalizability to other age and 
ethnic groups and women. The strong correlation 
between systolic and diastolic blood pressure and 
microalbuminuria in both the whole population 
and in nondiabetic males shows that the blood 
pressure has an important role for the development 
of albuminuria. 
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